Overview

Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer

Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of two drugs as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation.
Phase:
Phase 2
Details
Lead Sponsor:
Betta Pharmaceuticals Co., Ltd.
Collaborator:
The First Affiliated Hospital of Xiamen University